NOVOCURE LIMITED

(NVCR)
  Report
Delayed Nasdaq  -  04:00 2022-07-05 pm EDT
74.52 USD   +1.66%
07/05Evercore ISI Downgrades NovoCure to Underperform From In-Line
MT
07/01Novocure to Report Second Quarter 2022 Financial Results
BU
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NovoCure's Q1 Net Loss Flat, Revenue Rises

04/28/2022 | 08:54am EDT


© MT Newswires 2022
All news about NOVOCURE LIMITED
07/05Evercore ISI Downgrades NovoCure to Underperform From In-Line
MT
07/01Novocure to Report Second Quarter 2022 Financial Results
BU
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Index
CI
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Growth Index
CI
06/21NovoCure Enrolls First Patient in Study of Tumor Treating Fields, Keytruda Combination ..
MT
06/21Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields T..
BU
06/21Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields T..
CI
06/10NOVOCURE LTD : Change in Directors or Principal Officers, Amendments to Articles of Inc. o..
AQ
06/06HC Wainwright Initiates NovoCure at Buy, Sets Price Target at $115
MT
06/03Novocure Falls 5%, Zai Lab Rises 8%; Companies Report Study Results
DJ
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 552 M - -
Net income 2022 -62,6 M - -
Net Debt 2022 293 M - -
P/E ratio 2022 -128x
Yield 2022 -
Capitalization 7 794 M 7 794 M -
EV / Sales 2022 14,7x
EV / Sales 2023 13,6x
Nbr of Employees 1 167
Free-Float 86,7%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 74,52 $
Average target price 99,11 $
Spread / Average Target 33,0%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED-2.37%7 794
MASIMO CORPORATION-53.58%7 585
SHOCKWAVE MEDICAL, INC.13.17%7 224
GETINGE AB-38.83%6 246
IRAY TECHNOLOGY COMPANY LIMITED-6.22%5 032
PENUMBRA, INC.-55.97%4 767